Skip to main content
. 2021 Jan 11;76(5):929–936. doi: 10.1093/gerona/glaa295

Table 1.

Characteristics at the Time of Randomization, by Treatment Arm, for Participants in the Diabetes Prevention Program Outcomes Study (DPPOS) Who Underwent Frailty Assessments at Year 8

Characteristic Lifestyle Metformin Placebo Overall
(n = 787) (n = 803) (n = 795) (n = 2385)
Age at randomization (years) 51.3 (10.6) 51.5 (9.67) 50.5 (9.70) 51.1 (10.0)
Women (%) 67.9 66.1 68.9 67.6
Race/ethnicity (%)
 White 53.5 55.5 53.8 54.3
 African American 19.7 21.3 20.6 20.5
 Hispanic 14.5 14.6 14.7 14.6
 American Indian 6.2 5.1 6.0 5.8
 Asian 6.1 3.5 4.8 4.8
Education (%)
 ≤12 years 74.1 71.5 75.0 73.5
 13–16 years 25.9 28.5 25.0 26.5
Fasting glucose (mg/dL) 106 (8.08) 107 (8.61) 107 (8.62) 107 (8.44)
HbA1c % 5.91 (0.49) 5.92 (0.50) 5.93 (0.50) 5.92 (0.50)
BMI (kg/m2) 33.5 (6.40) 33.7 (6.45) 34.0 (6.59) 33.7 (6.48)
Systolic blood pressure (mm Hg) 123 (14.7) 124 (15.0) 123 (14.4) 123 (14.7)
Diastolic blood pressure (mm Hg) 78.2 (9.27) 78.1 (9.49) 78.0 (9.26) 78.1 (9.34)
Leisure physical activity (MET-h/wk) 15.6 (21.6) 17.0 (22.5) 17.5 (32.3) 16.7 (25.9)
MOS SF-36 physical component 50.7 (6.79) 50.1 (7.17) 50.4 (7.22) 50.4 (7.07)
MOS SF-36 mental component 53.9 (7.12) 54.1 (7.62) 54.2 (6.77) 54.1 (7.18)
Beck Depression Inventory (BDI) 4.42 (4.37) 4.35 (4.26) 4.42 (4.45) 4.39 (4.36)

Note. BMI = body mass index; HbA1c = glycosylated hemoglobin; MET = rate of energy expenditure while at rest; MOS SF = Medical Outcomes Study Short Form. Data for continuous variables are presented as mean (SD). Data for categorical variables are presented as percentage. There were no significant treatment arm differences.